The July 23-24, 2026, FDA Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommending BPC-157 for the 503A Bulk Drug Substances List represents the primary recent catalyst for trader positioning on Category 1 placement. This advisory step followed April 2026 removal from Category 2 restrictions but does not authorize compounding, as full reclassification requires FDA acceptance of the recommendation followed by notice-and-comment rulemaking, a process that historically spans eight to twelve months. FDA career scientists opposed the addition, citing limited human safety and efficacy data, while committee dynamics and broader agency priorities under the current administration influence the timeline. As of mid-September 2026, no final rulemaking announcement has occurred, leaving near-term resolution dependent on agency action within any specific market window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedNEW
Dec 31, 2026
December 31, 2026
54%
$4,648 Vol.
December 31, 2026
$2,646 Vol.
54%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23-24, 2026, FDA Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommending BPC-157 for the 503A Bulk Drug Substances List represents the primary recent catalyst for trader positioning on Category 1 placement. This advisory step followed April 2026 removal from Category 2 restrictions but does not authorize compounding, as full reclassification requires FDA acceptance of the recommendation followed by notice-and-comment rulemaking, a process that historically spans eight to twelve months. FDA career scientists opposed the addition, citing limited human safety and efficacy data, while committee dynamics and broader agency priorities under the current administration influence the timeline. As of mid-September 2026, no final rulemaking announcement has occurred, leaving near-term resolution dependent on agency action within any specific market window.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Market Opened: Jun 22, 2026, 10:10 PM ET
Volume
$4,648End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23-24, 2026, FDA Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommending BPC-157 for the 503A Bulk Drug Substances List represents the primary recent catalyst for trader positioning on Category 1 placement. This advisory step followed April 2026 removal from Category 2 restrictions but does not authorize compounding, as full reclassification requires FDA acceptance of the recommendation followed by notice-and-comment rulemaking, a process that historically spans eight to twelve months. FDA career scientists opposed the addition, citing limited human safety and efficacy data, while committee dynamics and broader agency priorities under the current administration influence the timeline. As of mid-September 2026, no final rulemaking announcement has occurred, leaving near-term resolution dependent on agency action within any specific market window.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$4,648End Date
Jan 1, 2027Market Opened
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The July 23-24, 2026, FDA Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) recommending BPC-157 for the 503A Bulk Drug Substances List represents the primary recent catalyst for trader positioning on Category 1 placement. This advisory step followed April 2026 removal from Category 2 restrictions but does not authorize compounding, as full reclassification requires FDA acceptance of the recommendation followed by notice-and-comment rulemaking, a process that historically spans eight to twelve months. FDA career scientists opposed the addition, citing limited human safety and efficacy data, while committee dynamics and broader agency priorities under the current administration influence the timeline. As of mid-September 2026, no final rulemaking announcement has occurred, leaving near-term resolution dependent on agency action within any specific market window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions